Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 328

Process and Tools for Making Heparin Sulfate Proteoglycans and Fusion Proteins

Inventors: Merton Bernfield, Scott Saunders

Invention Types: Therapeutics

Research Areas: Metabolic Disease, Surgery/Wound Healing, Audiology, Infectious Disease

Keywords:

For More Information Contact:  Yen, Alan

 

Invention Description:

Heparan sulfate chains added as post-translational modifications give certain proteins a unique ability to bind with high specficity to other macromolecules including growth factors, cell adhesive molecules, viral and parasitic pathogens as well as enzymes,and an ability to stabilize and or modify the activity of these ligands. This invention uses the heparan sulfate attachment region of syndecan-1 to genetically engineer heparan sulfate moieties onto other proteins. A small region of cDNA, encoding a region of syndecan sufficient for attachment and synthesis of a heparan sulfate chain, is ligated with a cDNA encoding the protein of interest, transfected into eukaryotic cells, resulting in the production of a new macromolecule, containing a heparan sulfate chain. This chimeric molecule would have new biological properties conferred by the presence of the heparan sulfate chains. The heparan sulfate chain attachment and synthesis region (HS-ASR) of syndecan could be covalently cross-linked to various other organic and non organic molecules such as pharmaceuticals, prosthetic devices, etc, after expression by itself and purification. Furthermore the construction of chimeras including HS-ASR's from different syndecans might produce products with distinct activities.|

The invention would have potential utility in at least the following areas:|

1) Growth Factors - Production of chimeric moleculs with heparin binding growth factors would result in growth factors with improved stability, activity and possibly new activities.

2) Anti-infective Agents - Viral and parasitic pathogens that utilize cell surface heparan surface as binding sites might be blocked by cell-type-specfic heparan sulfate. Furthermore, these heparan sulfate containing molecules can be covalently linked to anti-infective drugs, thus improving their delivery specifically to infected cells.

3) Enzyme/Enzyme Inhibitors - Heparin binding enzymes and enzymes inhibitors may be expressed as chimeras containing heparan sulfate chains with constitutively modified activity.

4) Adhesive molecules - chimeras of cell binding proteins could have enhanced properties as pharmaceuticals (wound repair), research reagents (cell culture substrates), and biomaterials (prosthetic devices) due to their ability to both bind cells ans cellular growth factors.

5) Anti-adhesive molecules - Competitive inhibitors of cell binding, made into -dimers- through the addition of these syndecan heparan sulfate chains, could have improved activity as anti-adhesive molecules.|

Applications:

Genomics

Competitive Advantages:

Much has been published in the research literature about the fact that syndecan molecules serve as co-receptors and docking mechanisms for many growth factors and signaling molecules on the surface of mammalian cells. It is believed that such molecules and/or drugs that affect them can serve as modulators of cell signaling activity.

Business Opportunity:

Non-Exclusive License

IPStatus: Patented